Novo Nordisk Says Health Canada Approves Wegovy (Semaglutide Injection) To Reduce Risk Of Non-Fatal Myocardial Infarction
Novo Nordisk Says Health Canada Approves Wegovy (Semaglutide Injection) To Reduce Risk Of Non-Fatal Myocardial Infarction
諾和諾德表示，加拿大衛生部批准了Wegovy（塞曼魯肽注射劑）以降低非致命性心肌梗死風險
Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2. It is the first Health Canada approved treatment to support both chronic weight management and to reduce the risk of non-fatal MI.
Wegovy（西馬魯肽注射液）現已獲得批准，用於降低患有既往心血管疾病且BMI等於或大於27 kg/m²的成年人非致命性心肌梗塞的風險。這是健康加拿大批准的首個既有助於慢性體重管理又可降低非致命性心肌梗塞風險的治療方案。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間